Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bierman, P. J.
Right arrow Articles by Armitage, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bierman, P. J.
Right arrow Articles by Armitage, J. O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1370-1377, 2002
© 2002 European Society for Medical Oncology

Original Paper

The International Prognostic Factors Project score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

P. J. Bierman1,+, J. C. Lynch2, R. G. Bociek1, V. L. Whalen1, A. Kessinger1, J. M. Vose1 and J. O. Armitage1

1 Department of Internal Medicine, Section of Oncology-Hematology; 2 Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

Received 22 November 2001; revised 25 January 2002; accepted 11 February 2002

Background:

The International Prognostic Factors Project on Advanced Hodgkin’s Disease developed a seven-factor prognostic score consisting of serum albumin, hemoglobin, gender, stage, age, leukocytosis and lymphocytopenia for newly diagnosed Hodgkin’s disease patients who receive chemotherapy. The purpose of this study was to determine whether this prognostic score would also be useful for Hodgkin’s disease patients undergoing autologous hematopoietic stem cell transplantation.

Patients and methods:

We performed a retrospective review of 379 patients who had autologous transplants for Hodgkin’s disease, at the University of Nebraska Medical Center between October 1984 and December 1999. Multivariate analysis was performed to determine whether the prognostic factors identified by the International Prognostic Factors Project adversely influenced event-free survival (EFS) or overall survival (OS).

Results:

Low serum albumin, anemia, age and lymphocytopenia were associated with poorer EFS and OS. Gender, stage and leukocytosis were not associated with significantly poorer outcomes. Estimated 10-year EFS was 38%, 23% and 7% for patients with 0–1, 2–3 or >=4 of the adverse prognostic characteristics identified by the International Prognostic Factors Project, respectively.

Conclusions:

The prognostic score for advanced disease is also useful for relapsed and refractory Hodgkin’s disease patients undergoing high-dose therapy followed by autologous hematopoietic stem cell transplantation.

Key words: autologous transplantation, Hodgkin’s disease, prognostic factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
B. W. Schot, J. M. Zijlstra, W. J. Sluiter, G. W. van Imhoff, J. Pruim, W. Vaalburg, and E. Vellenga
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
Blood, January 15, 2007; 109(2): 486 - 491.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Asano, A. Oshiro, K. Matsuo, Y. Kagami, F. Ishida, R. Suzuki, T. Kinoshita, Y. Shimoyama, J.-I. Tamaru, T. Yoshino, et al.
Prognostic Significance of T-Cell or Cytotoxic Molecules Phenotype in Classical Hodgkin's Lymphoma: A Clinicopathologic Study
J. Clin. Oncol., October 1, 2006; 24(28): 4626 - 4633.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
N. L. Bartlett
Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy
Hematology, January 1, 2005; 2005(1): 245 - 251.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Montalban, J. F. Garcia, V. Abraira, L. Gonzalez-Camacho, M. M. Morente, J. L. Bello, E. Conde, M. A. Cruz, R. Garcia-Sanz, J. Garcia-Larana, et al.
Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group
J. Clin. Oncol., May 1, 2004; 22(9): 1664 - 1673.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.